Relmada Therapeutics Stock Analysis
| RLMD Stock | USD 4.08 0.44 12.09% |
IPO Date 9th of October 2014 | 200 Day MA 1.0887 | 50 Day MA 2.6086 | Beta 0.833 |
Relmada Therapeutics holds a debt-to-equity ratio of 0.042. At present, Relmada Therapeutics' Debt To Equity is projected to slightly decrease based on the last few years of reporting. The current year's Total Debt To Capitalization is expected to grow to 0, whereas Short and Long Term Debt Total is forecasted to decline to about 120.4 K. Relmada Therapeutics' financial risk is the risk to Relmada Therapeutics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Relmada Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Relmada Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Relmada Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Relmada Therapeutics' stakeholders.
For many companies, including Relmada Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Relmada Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Relmada Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 28.8204 | Book Value 0.285 | Enterprise Value | Enterprise Value Ebitda 0.5431 | Shares Float 65.4 M |
Relmada Therapeutics is undervalued with Real Value of 4.49 and Target Price of 5.5. The main objective of Relmada Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Relmada Therapeutics is worth, separate from its market price. There are two main types of Relmada Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Relmada Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Relmada Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Relmada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. Relmada Stock Analysis Notes
About 19.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.78. Relmada Therapeutics last dividend was issued on the 30th of September 2019. The entity had 1:4 split on the 30th of September 2019. Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases and other disorders. The company was founded in 2004 and is headquartered in Coral Gables, Florida. Relmada Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people. To find out more about Relmada Therapeutics contact MBA MBA at 786 629 1376 or learn more at https://www.relmada.com.Relmada Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Relmada Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Relmada Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Relmada Therapeutics had very high historical volatility over the last 90 days | |
| Relmada Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (79.98 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Relmada Therapeutics currently holds about 211.96 M in cash with (51.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Relmada Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Relmada regains Nasdaq compliance on minimum bid price - MSN |
Relmada Largest EPS Surprises
Earnings surprises can significantly impact Relmada Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-03-17 | 2024-12-31 | -0.7 | -0.62 | 0.08 | 11 | ||
2024-11-06 | 2024-09-30 | -0.64 | -0.72 | -0.08 | 12 | ||
2025-08-07 | 2025-06-30 | -0.4 | -0.3 | 0.1 | 25 |
Relmada Therapeutics Environmental, Social, and Governance (ESG) Scores
Relmada Therapeutics' ESG score is a quantitative measure that evaluates Relmada Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Relmada Therapeutics' operations that may have significant financial implications and affect Relmada Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Relmada Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Renaissance Technologies Corp | 2025-06-30 | 150.1 K | Adar1 Capital Management Llc | 2025-06-30 | 130 K | Jane Street Group Llc | 2025-06-30 | 114.4 K | State Street Corp | 2025-06-30 | 106.7 K | We Are One Seven, Llc | 2025-06-30 | 100 K | Two Sigma Investments Llc | 2025-06-30 | 95.4 K | Susquehanna International Group, Llp | 2025-06-30 | 65.8 K | Northern Trust Corp | 2025-06-30 | 59.6 K | Lmr Partners Llp | 2025-06-30 | 55.1 K | Driehaus Capital Management Llc | 2025-06-30 | 740 K | Blackrock Inc | 2025-06-30 | 508 K |
Relmada Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 330.73 M.Relmada Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.01) | (2.11) | |
| Return On Capital Employed | (2.13) | (2.02) | |
| Return On Assets | (2.01) | (2.11) | |
| Return On Equity | (2.59) | (2.46) |
Management Efficiency
Relmada Therapeutics has return on total asset (ROA) of (1.0241) % which means that it has lost $1.0241 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.9679) %, meaning that it created substantial loss on money invested by shareholders. Relmada Therapeutics' management efficiency ratios could be used to measure how well Relmada Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of February 19, 2026, Return On Tangible Assets is expected to decline to -2.11. The current year's Return On Capital Employed is expected to grow to -2.02. At present, Relmada Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 68.2 M, whereas Non Currrent Assets Other are forecasted to decline to about 18.8 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.06 | 1.01 | |
| Tangible Book Value Per Share | 1.06 | 1.01 | |
| Enterprise Value Over EBITDA | (0.14) | (0.13) | |
| Price Book Value Ratio | 0.51 | 0.48 | |
| Enterprise Value Multiple | (0.14) | (0.13) | |
| Price Fair Value | 0.51 | 0.48 | |
| Enterprise Value | 18.4 M | 14.2 M |
Relmada Therapeutics has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Technical Drivers
As of the 19th of February, Relmada Therapeutics holds the Semi Deviation of 3.99, risk adjusted performance of 0.0374, and Coefficient Of Variation of 2721.2. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Relmada Therapeutics, as well as the relationship between them. Please check Relmada Therapeutics treynor ratio, as well as the relationship between the downside variance and kurtosis to decide if Relmada Therapeutics is priced some-what accurately, providing market reflects its current price of 4.08 per share. Given that Relmada Therapeutics has jensen alpha of 0.1602, we recommend you to check out Relmada Therapeutics's recent market performance to make sure the company can sustain itself at a future point.Relmada Therapeutics Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two.
Relmada Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Relmada Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Relmada Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Relmada Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Relmada Therapeutics Outstanding Bonds
Relmada Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Relmada Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Relmada bonds can be classified according to their maturity, which is the date when Relmada Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| TOMARI 1512 28 SEP 26 Corp BondUS75951AAQ13 | View | |
| RELIANCE STL ALUM Corp BondUS759509AB87 | View | |
| US759509AG74 Corp BondUS759509AG74 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Relmada Therapeutics Predictive Daily Indicators
Relmada Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Relmada Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Relmada Therapeutics Forecast Models
Relmada Therapeutics' time-series forecasting models are one of many Relmada Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Relmada Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Relmada Therapeutics Bond Ratings
Relmada Therapeutics financial ratings play a critical role in determining how much Relmada Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Relmada Therapeutics' borrowing costs.| Piotroski F Score | 3 | Frail | View |
| Beneish M Score | (6.58) | Unlikely Manipulator | View |
Relmada Therapeutics Debt to Cash Allocation
Many companies such as Relmada Therapeutics, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Relmada Therapeutics currently holds 10.3 M in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Relmada Therapeutics has a current ratio of 11.17, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Relmada Therapeutics' use of debt, we should always consider it together with its cash and equity.Relmada Therapeutics Total Assets Over Time
Relmada Therapeutics Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Relmada Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Relmada Therapeutics Debt Ratio | 0.0805 |
Relmada Therapeutics Corporate Bonds Issued
Most Relmada bonds can be classified according to their maturity, which is the date when Relmada Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Relmada Net Debt
Net Debt |
|
About Relmada Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Relmada Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Relmada shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Relmada Therapeutics. By using and applying Relmada Stock analysis, traders can create a robust methodology for identifying Relmada entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (1.75) | (1.83) | |
| Operating Profit Margin | (1.75) | (1.83) | |
| Net Loss | (1.75) | (1.83) | |
| Gross Profit Margin | 0.31 | 0.26 |
Current Relmada Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Relmada analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Relmada analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 5.5 | Hold | 3 | Odds |
Most Relmada analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Relmada stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Relmada Therapeutics, talking to its executives and customers, or listening to Relmada conference calls.
Relmada Stock Analysis Indicators
Relmada Therapeutics stock analysis indicators help investors evaluate how Relmada Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Relmada Therapeutics shares will generate the highest return on investment. By understating and applying Relmada Therapeutics stock analysis, traders can identify Relmada Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 4.1 M | |
| Common Stock Shares Outstanding | 30.2 M | |
| Total Stockholder Equity | 35.5 M | |
| Total Cashflows From Investing Activities | 51.6 M | |
| Cash And Short Term Investments | 44.9 M | |
| Cash | 3.9 M | |
| Accounts Payable | 4.1 M | |
| Net Debt | -3.9 M | |
| 50 Day M A | 2.6086 | |
| Total Current Liabilities | 10.3 M | |
| Other Operating Expenses | 83.9 M | |
| Non Current Assets Total | 22 K | |
| Non Currrent Assets Other | 22 K | |
| Stock Based Compensation | 30.2 M |
Complementary Tools for Relmada Stock analysis
When running Relmada Therapeutics' price analysis, check to measure Relmada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relmada Therapeutics is operating at the current time. Most of Relmada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relmada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relmada Therapeutics' price. Additionally, you may evaluate how the addition of Relmada Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |